Foxo technologies receives notice from nyse american regarding late filing of quarterly report on form 10-q

Minneapolis--(business wire)--foxo technologies inc. (nyse american: foxo) (“foxo” or the “company”), a leader in the field of epigenetic biomarker technology, announced that on november 21, 2023, it received a notice from nyse regulation stating that the company is not in compliance with the continued listing standards of the nyse american (the “exchange”) under the timely filing criteria set forth in section 1007 of the nyse american company guide (the “company guide”). the non-compliance res.
FOXO Ratings Summary
FOXO Quant Ranking